EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
獨家報道：“如果ED療法能夠場外交易，處方勃起功能障礙市場可能增長三倍，”Petros Pharma總裁表示。
Petros Pharmaceuticals Inc (NASDAQ:PTPI) is a pharmaceutical company focusing on men's health therapeutics.
Petros Pharmaceuticals股份有限公司（納斯達克：PTPI）是一家以男性健康治療爲重點的藥品公司。
In an interview with Benzinga, Fady Boctor, the President and Chief Commercial Officer of Petros Pharmaceuticals, said the company aims to expand access of key prescription pharmaceuticals as over-the-counter (OTC) treatment options.
在接受本新聞的採訪時，Petros Pharmaceuticals總裁兼首席商業官Fady Boctor表示，該公司旨在將主要處方藥物作爲場外交易（OTC）治療期權擴大使用範圍。
Boctor added that Petros is a pure play in the Rx-to-OTC self-care market, focused on bringing its current lead erectile dysfunction (ED) therapeutic OTC while developing a pathway that would take future therapeutics OTC as well.
Boctor補充說，Petros是Rx-to-OTC自我保健市場的純玩家，專注於將其當前的領先勃起功能障礙（ED）治療作爲OTC藥物，並開發一條可以使未來治療藥物也成爲OTC的路徑。
"Rx-to-OTC is emerging as a substantial self-care industry among...
“Rx-to-OTC正在...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。